Journal
VISCERAL MEDICINE
Volume 33, Issue 5, Pages 358-366Publisher
KARGER
DOI: 10.1159/000480383
Keywords
Peptide receptor radionuclide therapy, PRRT; Neuroendocrine tumor, NET; Theranostics; Diagnosis; Positron emission tomography/computed tomography, PET/CT
Categories
Ask authors/readers for more resources
Somatostatin receptor positron emission tomography/computed tomography using Ga-68-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life. (C) 2017 S. Karger GmbH, Freiburg
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
